CJC-1295 with DAC (5 mg Vial) Dosage Protocol
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analog modified with a maleimide group that covalently binds serum albumin, extending half-life from minutes to ~6–8 days.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and twice-weekly dosing
Standard / Gradual Approach (2 mL = 2500 mcg/mL)
| Week | Per-Injection Dose (mcg) | Units (per injection) (mL) | Weekly Total |
|---|---|---|---|
| Weeks 1–2 | 300 mcg (0.3 mg) | 12 units (0.12 mL) | 600 mcg/week |
| Weeks 3–4 | 500 mcg (0.5 mg) | 20 units (0.20 mL) | 1000 mcg/week |
| Weeks 5–6 | 750 mcg (0.75 mg) | 30 units (0.30 mL) | 1500 mcg/week |
| Weeks 7–12 | 1000 mcg (1 mg) | 40 units (0.40 mL) | 2000 mcg/week |
Frequency: Inject twice weekly subcutaneously (e.g., Monday/Thursday or Tuesday/Friday). The extended 6–8-day half-life from the DAC modification supports less frequent dosing compared to non-DAC GHRH analogs. Once-weekly dosing is also studied; adjust frequency based on protocol requirements.
For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
- Gently swirl/roll until dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
Supplies Needed
Plan based on an 8–16 week twice-weekly protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (CJC-1295 DAC, 5 mg each) | 8 weeks: approximately 3 vials required (~10.2 mg total) 12 weeks: approximately 4 vials required (~18.2 mg total) 16 weeks: approximately 6 vials required (~26.2 mg total) |
| Insulin Syringes (U-100) | Per week: 2 syringes (twice weekly) 8 weeks: 16 syringes 12 weeks: 24 syringes 16 weeks: 32 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (3 vials): 6 mL — 1 bottle required (10 mL each) 12 weeks (4 vials): 8 mL — 1 bottle required (10 mL each) 16 weeks (6 vials): 12 mL — 2 bottles required (10 mL each) |
| Alcohol Swabs | Per week: 4 swabs (2 per injection × 2 injections) 8 weeks: 32 swabs — 1 box required (100 swabs each) 12 weeks: 48 swabs — 1 box required (100 swabs each) 16 weeks: 64 swabs — 1 box required (100 swabs each) |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
CJC-1295 is a synthetic GHRH analog with four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) for stability against DPP-4. The DAC version adds a maleimide N-(2-aminoethyl)-2-maleimide group that covalently attaches to serum albumin via a free cysteine, extending half-life dramatically.
It binds pituitary GHRH receptors, raising baseline GH and IGF-1 levels for sustained periods. The continuous elevation differs from physiological pulsatile GH and is one reason combinations with GHRPs (ipamorelin) are popular — GHRPs provide pulsatile peaks atop CJC-1295's elevated baseline.
Potential Benefits & Side Effects
Potential Benefits
- Sustained GH/IGF-1 elevation from 1–2 weekly injections.
- Improvements in body composition reported.
- Often combined with ipamorelin for pulsatile + sustained pattern.
- Recovery and sleep-quality improvements anecdotally reported.
Side Effect Profile
- Injection-site reactions (most common).
- Mild fluid retention.
- Tingling/numbness in extremities (carpal-tunnel-like).
- Headache.
- Continuous GH elevation may blunt natural pulsatility long-term.
Lifestyle Factors
- Resistance training to leverage anabolic effects.
- Adequate sleep supports GH-axis function.
- Avoid late-evening high-fat meals.
- Monitor fasting glucose periodically.
Injection Technique
- Subcutaneous into abdomen, thigh, or upper arm.
- Rotate sites with each dose.
- 90° angle with short insulin needle.